NASDAQ: LYRA - Lyra Therapeutics, Inc.

Yield per half year: -31.96%
Sector: Healthcare

Share chart Lyra Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

more details
The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-05-01
ISIN US55234L1052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://lyratherapeutics.com
Цена ао 6.13
Change price per day: +5.48% (0.1806)
Change price per week: +5.83% (0.18)
Change price per month: +0.2632% (0.19)
Change price per 3 month: -28.3% (0.2657)
Change price per half year: -31.96% (0.28)
Change price per year: -96.36% (5.24)
Change price per 3 year: -95.81% (4.55)
Change price per 5 year: 0% (0.1905)
Change price per 10 year: 0% (0.1905)
Change price per year to date: -9.37% (0.2102)
All parameters

Underestimation

Title Value Grade
P/S 159.19 1
P/BV 2.77 6
P/E 0 0
EV/EBITDA -3.87 0
Total: 3.5

Efficiency

Title Value Grade
ROA, % -43.96 0
ROE, % -70.1 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.412 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 29.83 4
Yield Ebitda, % 295.45 10
Yield EPS, % -51.03 0
Total: 6.8
More

Institutions Volume Share, %
Perceptive Advisors LLC 12757562 21.35
Nantahala Capital Management, LLC 8100436 13.56
Vestal Point Capital, LP 3000000 5.02
Point72 Asset Management, L.P. 3000000 5.02
Citadel Advisors Llc 2861255 4.79
Samsara BioCapital, LLC 2780261 4.65
VR Adviser, LLC 2575593 4.31
Rosalind Advisors, Inc. 1888720 3.16
PURA VIDA INVESTMENTS, LLC 1413242 2.37
Ikarian Capital, LLC 1254384 2.1

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.00348 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00096 38.04 0.6026
ProShares UltraPro Russell2000 0.0003 89.82 1.47873
ProShares Hedge Replication ETF 0.00008 5.92 1.47892
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264



Head Job title Payment Year of birth
Dr. Harlan W. Waksal M.D. Executive Chairman 210.06k 1953 (72 years)
Dr. Maria Palasis Ph.D. CEO, President & Director 942.7k 1965 (60 years)
Dr. Carmichael S. Roberts Jr., Ph.D. Co-Founder N/A 1969 (56 years)
Mr. Jason Cavalier CFO, Treasurer & Secretary 464.11k 1973 (52 years)
Mr. Ray Knox Vice President of Operations N/A
Ms. Vineeta Belanger Ph.D. Senior Vice President of Clinical Affairs N/A
Mr. Ronan P. O'Brien J.D. Chief Legal Officer 1973 (52 years)
Dr. Robert Richard Ph.D. Senior Vice President of Technical Operations 1958 (67 years)
Dr. Robert Kern M.D. Chief Clinical Advisor
Ms. Gloria Cosgrove Senior Vice President of Quality

Address: United States, Watertown. MA, 480 Arsenal Way - open in Google maps, open in Yandex maps
Website: https://lyratherapeutics.com